Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) announced management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City.
Presenters include Ben Zeskind (CEO), Igor Matushansky M.D. (CMO), Harold “E.B.” Brakewood (CBO) and Mallory Morales, CPA (CAO, Treasurer). Format: company presentation and 1x1 investor meetings. Presentation time: December 4, 11:10–11:30 a.m. ET, Staten Island Track (Kennedy 1, 4th Floor). The presentation will be webcast live and archived in the Investor Relations section under Events & Presentations.
Details
News Market Reaction – IMRX
On Nov 25, the day this news came out, IMRX closed 0.67% below the previous close.
Data tracked by StockTitan Argus for the Nov 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Format: Company Presentation and 1x1 investor meetings.
Presentation time: December 4, 11:10-11:30 a.m. ET, Staten Island Track (Kennedy 1, 4th Floor).
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Carson Creehan
202-878-8330
Carson.creehan@padillaco.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.